Phase 3 trial of Nexavar in patients with NSCLC fails to meet primary endpoint
23:35 EDT 23 May 2012 | PharmaBiz
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. have reported that the phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non─squamous non─small cell lung cancer (NSCLC) whose dis..
Original Article: Phase 3 trial of Nexavar in patients with NSCLC fails to meet primary endpoint
More From BioPortfolio on "Phase 3 trial of Nexavar in patients with NSCLC fails to meet primary endpoint"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
